[Cost-effectiveness analysis of samario-153 (Quadramet) for the treatment of patients with prostate cancer and bone metastases].
OBJECTIVE
To evaluate the cost-effectiveness of samarium [153Sm-EDTMP] (Quadramet) compared to conventional therapy in the treatment of pain in patients with prostate cancer and bone metastases.


METHODS
A decision tree model for the treatment of bone pain due to metastases was adapted to the Spanish context. The model represents the standard treatment patterns in Spain for the study population. The time-course of the model is 4 months and it computes an estimate for the cost of pain control per patient. The effectiveness data for the model derive from a randomised trial. The current treatment patterns have been established according to the consensus opinions of a group of medical experts.


RESULTS
The cost of pain control per patient is euro 12,515.39 for conventional therapy and euro 5,595.52 for samarium-153 (Quadramet) therapy. The incremental cost-effectiveness analysis shows that samarium-153 (Quadramet) is a dominant therapy. It presents lower costs and higher efficacy than the conventional strategy. The sensitivity analyses showed these results to be robust.


CONCLUSIONS
Samarium-153 (Quadramet) is cost-effective in treating pain in patients with prostate cancer and bone metastases.
Velasco Latrás
María
M
SOIKOS, Centro de Estudios en Economía de la Salud y de la Política Social, S.L., Barcelona, Spain.
Carreras Coderch
Luis
L
Antoñanzas Villar
Fernando
F
Coya Viña
Juan
J
Martín Comín
José
J
Martínez Carderón
Francisco
F
Nieto Martín-Bejarano
José
J
Sáenz Cusí
Alberto
A
Serrano Bermúdez
Gala
G
Echevarría Icaza
Amaya
A
D000230:Adenocarcinoma / Q000188:drug therapy / Q000191:economics* / Q000556:secondary; D018712:Analgesics, Non-Narcotic / Q000191:economics* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000191:economics* / Q000556:secondary; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D008297:Male; D018803:Models, Economic; D009942:Organometallic Compounds / Q000191:economics* / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000191:economics* / Q000627:therapeutic use; D010147:Pain Measurement / Q000379:methods; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000191:economics* / Q000473:pathology; D011868:Radioisotopes / Q000191:economics*; D012493:Samarium / Q000191:economics; D016896:Treatment Outcome
D018712:Analgesics, Non-Narcotic; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011868:Radioisotopes; D012493:Samarium; C061972:samarium Sm-153 lexidronam